click below
click below
Normal Size Small Size show me how
Anticancer Drugs
Blood and Lymph Medical Pharmacology Anticancer Drugs
| Question | Answer |
|---|---|
| Major categories of alkylating agents | Nitrogen Mustards Nitrosoureas |
| Nitrogen Mustards (Drug Names) | Cyclophosphamide Mechlorethamine Melphalan |
| Nitrosoureas (Drug Names) | Carmustine Lomustine |
| Platinum complexes (Drug Names) | Cisplatin |
| Major Categories of Antimetabolites | Antifolates Pyrimidine antimetabolites Purine antimetabolites |
| Major Categories of Natural Product Anticancer Drugs | Antimitotic drugs Epipodophyllotoxins Camptothecins Antibiotics Enzymes |
| Major Categories of Hormones and Antagonists | Glucocorticoids Anti-estrogens Aromatase inhibitors |
| Targeted Agents (Drug Names) | Bortezomib Hydroxyurea Imatnib Trastuzumab Bevacizumab |
| Alkylating Agents: Primary Mechanism of Antitumor Action | Alkylation of DNA |
| The major site of action for Alkylating Agents | N7 position of Guanine |
| Alkylating agents form highly reactive alkyl groups by binding _______________ to nucleophilic targets. | Covalently |
| Effects of Alkylation on DNA | Excessive Cross Linking (bifunctional) DNA Strand Breaks (monofunctional) Miscoding of DNA |
| General Toxicities of Alkylating Agents | Potentially Carcinogenic, Mutagenic, Teratogenic Reproductive system toxicity Veno-Occlusive Disease of the liver from vascular endothelial damage. Strong Vesicant Properties-->damaged veins |
| Unique feature of Nitrogen Mustards | Clothes pin structure crosslinks DNA |
| Cyclophosphamide is a __________________ that is activated in the ____________________. | prodrug; liver |
| The dose-limiting effect of cyclophosphamide is _________________, which allows for cyclophosphamide to also be used as a(n)____________________ | Bone marrow depression; immunosuppressant |
| Acute dose-limiting effect of Cyclophosphamide. | Hemorrhagic cystitis |
| ______________________is the metabolite that causes Hemorrhagic cystitis. | Acrolein |
| Treatment/prevention of hemorrhagic cystitis caused by cyclophosphamide. | -Aggressive hydration -Mesna (2-mercaptoethane sodium sulfonate) -N-acetylcysteine (NAC) |
| Action of Mesna and N-acetylcysteine | Scavenge for acrolein molecules. |
| Hemhorrhagic cystitis is _________ ___________ of the bladder that leads to hemorrhage. | diffuse inflammation |
| Nitrosorueas major site of action | O6 Guanine (Attack the DNA!) |
| Nitrosoureas, because they are highly lipophilic, are able to _____________ which makes them UNIQUELY useful in treating _________________. | cross the BBB; brain tumors |
| Major toxicities of Nitrosoureas | -Profound and delayed bone marrow depression -Multiple dose limiting toxicities (CNS, renal, hepatic, pulmonary) |
| Nitrosoureas are so toxic, you must track a patient's ____________________. | lifetime cumulative dose |
| Platinum Complexes (Drug Names) | Cisplatin |
| Cisplatin range of antitumor activity (major organs/tissue) | Testicular Ovarian Bladder |
| Cisplatin mechanism of action | Causes inter- and intra- strand DNA crosslinks. |
| How Cisplatin is modified in order to act. | Water replaces chloride in structure, creating a reactive molecule. |
| Environment for Cisplatin modification | Low chloride concentrations (occurs inside cells as well as in the urine which can lead to bladder problems) |
| Cisplatin Toxicity | -Severe Nausea and Vomiting -Anaphylactic like Reactions -Nephrotoxicity -Neurotoxicity |
| Cisplatin Dose-Limiting Toxicity | Nephrotoxicity |
| Nephrotoxicity by cisplatin is abrogated by _______________, __________________, and _________________. | Hydration; Chloride Diuresis; Amifostine |
| Major Categories of Antimetabolites | Antifolates Pyrimidine Antimetabolites Purine Antimetabolites |
| Antifolates (Drug Names) | Methotrexate |
| Methotrexate inhibits ___________________, which means that ____________________ is not converted into ____________________. The overall meaning of this is that methotrexate interrupts ____ ___________ synthesis of _______ and purine nucleotides. | Dihydrofolate Reductase (as well as other enzymes) Dihydrofolate Tetrahydrofolate de novo TMP |
| Methotrexate is often given with _______________ in a process called "_________________ _______________"to reduce toxicity in normal cells. | Leucovorin Leucovorin Rescue |
| Pyrimidine Analogs (Drug Names) | 5-Fluorouracil Capecitabine Cytarabine Gemcitabine |
| Cytarabine is also known as ____________. | ara-C |
| 5-Fluorouracil is one of the most widely used agents for ____________, _____________, and ___________________. | Basal Cell Carcinoma Breast Cancer Colorectal Cancer |
| Two main things that 5-FU does | Incorporates into nucleic acid Prevents generation of TTP |
| Target cells convert 5-FU to ______________, which covalently binds to the enzyme _________________. | 5F-dUMP Thymidylate synthetase |
| Dose limiting toxicities of 5-FU | GI mucositis Bone marrow depression |
| Effect of leucovorin when used with 5-FU | Enhances cytotoxic effects and toxicities |
| Prodrug that is converted to ara-CTP | Cytarabine |
| Cytarabine competes with this to inhibit DNA synthesis. | dCTP |
| Cytarabine is unstable in the blood so it requires this type of delivery. | Constant infusion over 5-7 days. |
| Cytarabine uses | Hematological (AML, ALL, non-Hodgkin's lymphoma) |
| Cytarabine toxicities | Bone Marrow Depression Hyperuricemia |
| Deoxycytidine analog used in breast, nonsmall cell lung, pancreatic, and ovarian cancer | Gemcitabine |
| Deoxycytidine analog used in breast, nonsmall cell lung, pancreatic, and ovarian cancer | Gemcitabine |
| Three major mechanisms of action of Gemcitabine | Inhibits ribonucleotide reductase, inhibits DNA polymerase, incorporates into DNA |
| Gemcitabine dose limiting toxicity | Myelosuppression |
| Ribonucleotide reductase function | Takes ribonucleotides and makes them deoxyribonucleotide. |
| Purine Analogs (Drug Names) | 6-Mercaptopurine (6-MP), 6 Thioguanine (6-TG) |
| Uses of 6-MP and 6-TG | ALL; AML; CML Acute lymphocytic leukemia; Acute myelogenous leukemia; Chronic myelogenous leukemia |
| Enzyme that activates Purine analogs from inactive parent form | HGPRT (hypoxanthine-guanine phosphoribosyltransferase) |
| Purine analogs Mechanisms of Action | Inhibit synthesis of purine nucleotides Incorporate into RNA and DNA |
| Enzyme that metabolizes 6-Mercaptopurine | Xanthine Oxidase |
| Drug that is given to protect kidneys against uric acid damage. | Allopurinol |
| Mechanism by which allopurinol inhibits uric acid production | Inhibition of Xanthine Oxidase |
| The dose of ________ must be lowered when allopurinol is used concurrently (and why) | 6-MP because allopurinol inhibits xanthine oxidase which also helps breakdown 6-MP. 6-MP could build up. |
| Purine analog side effects | Bone marrow depression; Hyperuricemia; Hepatotoxicity |
| Substance that can make a tumor resistant to all Natural Products drugs. | P-glycoprotein |
| Vincristine and Vinblastine mechanism of action | Inhibit microtubule polymerization |
| Vincristine Treatment of Choice | Induce remissions in Lymphocytic Leukemia |
| Vincristine Dose Limiting Tox | Neurological Toxicity: Peripheral Sensory neuropathy |
| Vinblastine Dose Limiting Tox | Myelosuppression (vinBlastine= Bone marrow) |
| Paclitaxel and Docetaxel mechanism of action | hyperstabilizes polymerized microtubules by binding to tubulin. Mitotic spindle can't breakdown inducing apoptosis. |
| Paclitaxel Dose Limiting Tox | Peripheral Neuropathy; Bone marrow depression. |
| Docetaxel Toxicities | Neurotoxicity (neurosensory and neuropathy);Bone marrow depression; Fluid Retention |
| Etoposide mechanism of action | Inhibits topoisomerase II |
| Etoposide use | Testicular Tumors; Small Cell Lung Cancer "Lance Armstrong Used This so that 'E TOP the world of cycling" |
| Topotecan use | Ovarian and Small Cell Lung Cancer |
| Irinotecan use | Metastatic Colon Carcinoma |
| Topotecan and Irinotecan inhibit this | Topoisomerase I |
| Irinotecan dose limiting toxicity | Diarrhea; Bone Marrow Depression |
| Anticancer drugs that cause something to go wrong with neuro system | |
| Dactinomycin mechanism of action. | Intercalates in DNA to block DNA/RNA synthesis. |
| Doxorunbin and Daunorubicin mechanisms of action (3) | 1. Intercalate into DNA 2. Inhibit topoisomerase II 3. Free radical formation because Fe complex is very reactive. |
| Daunorubicin Use | Acute Lymphocytic Leukemia (ALL); Acute Non-Lymphocytic Leukemia (ANLL) |
| Doxorubicin and Danorubicin Toxicity | Cardiotoxicity- chronic, cumulative, dose related, often irreversible |
| Bleomycin mechanism of action | DNA Strand Breakage by oxidative damage by DNA-bleomycin-Fe(II) complex. |
| Bleomycin toxicity | Pulmonary toxicity; Cutaneous toxicity "Lance Armstrong Didn't Use This because he didn't want to Bleo his chances" |
| Bleomycin pulmonary toxicity stages | Nonspecific pneumonitis-->Life threatening pulmonary fibrosis |
| Bleomycin pulmonary toxicity is _____________over a lifetime | Cumulative |
| Bleomycin pulmonary toxicity risk factors | Total Dose; Age>70; Underlying lung disease; High doses; High [Oxygen] |
| L-Asparaginase use | Standard for all Lymphocytic leukemia including ALL |
| L-Asparaginase Mechanism | Hydrolyzes circulating L-asparagine. For tumor cells that can't make L-asparagine, this depletes cells of it. |
| Hormones and Antagonists: Major Classes | Glucocorticoids; Anti-Estrogens; Aromatase Inhibitors |
| Prednisone (glucocorticoid) used for suppressing this. | Lymphocytes |
| Tamoxifen (Anti-Estrogen) Mechanism | Competitively binds to estrogen receptor |
| Tamoxifen Use | Brest tumors that are Estrogen Receptor Positive (ER+) |
| Risk reduction setting for tamoxifen use. | Women with Ductal Carcinoma in Situ; Women at High Risk for Breast Cancer |
| Anastrozole mechanisms of action | Inhibits: 1. Adrenal synthasis of steroids 2. Aromatase conversion of androgens to estrogens in peripheral tissues. |
| Anastrozole key use | Cases in which tamoxifen is no longer effective. |
| Bortezomib Use | Multiple Myeloma |
| Bortezomib mechanism | 1.Inhibits 26S proteasome which prevents degradation of proteins (initiating apoptosis). 2. Disrupts cell signaling pathways |
| Imatinib mechanism | Inhibits Bcr-Abl tyrosine kinase |
| Imatinib use | Chronic Myelogenous Leukemia |
| Trastuzumab mechanism | Block HER-2 receptor |
| Description of HER-2 receptor | Extremely aggressive pathway, cranks up metastasis, turns down apoptosis |
| Associated with HER-2 | Estrogen Receptor Negative Breast Cancer |
| Bevacizumab mechanism | Blocks vascular endothelial growth factor (VEGF) for anti-angiogenic action. |
| Hydroxyurea mechanism | Inhibits ribuncleotide reductase which is important for salvaging ribodiphos-->deoxyribodiphos |